ANI Pharmaceuticals enters development agreement with Sterling Pharmaceutical ANI Pharmaceuticals announced that it has entered into a fee-for-service development agreement for a generic drug product with Sterling Pharmaceutical Services. The product will be developed by Sterling and transferred into ANI's facilities for commercial manufacture and marketing. The current annual market for this product is $60M, according to IMS Health.
News For ANIP From The Last 14 Days
Check below for free stories on ANIP the last two weeks.